Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 2/20 | 0.37 |
| ▸ | ADK | P55263 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650370 | 0.84 | HSP90AA1 (0.50) | HSP90AA1ALDH1A1 | |
| SCHEMBL31463007 | 0.81 | KDM4E (0.50) | HSP90AA1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL22127663 | 0.81 | KDM4E (0.50) | HSP90AA1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL22121720 | 0.81 | TRPV1 (0.35) | ADORA1HSP90AA1MEN1KMT2AALDH1A1 | |
| SCHEMBL12501034 | 0.80 | TRPV1 (0.44) | — | |
| SCHEMBL23517029 | 0.79 | HSP90AA1 (0.41) | ADORA1ADORA2AAURKAHSP90AA1PRKACA | |
| SCHEMBL12424720 | 0.78 | ADORA1 (0.60) | ADORA1ADORA2AHSP90AA1MEN1KMT2A | |
| SCHEMBL2658228 | 0.78 | F2 (0.42) | ADORA2AL3MBTL1 | |
| SCHEMBL4359138 | 0.77 | TRPV1 (0.43) | HSP90AA1L3MBTL1 | |
| SCHEMBL22121733 | 0.74 | MAPT (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133074-B1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-12-09 | — | — | EP | disclosed |
| EP-3133074-B1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-12-09 | — | — | EP | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| EP-2746281-B1 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-04-26 | — | — | EP | disclosed |
| EP-2746281-B1 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-04-26 | — | — | EP | disclosed |
| EP-3133074-A2 | 7-AZAINDOLE DERIVATIVES | Merck Patent GmbH (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-3133074-A2 | 7-AZAINDOLE DERIVATIVES | Merck Patent GmbH (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-2670748-B1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-28 | — | — | EP | disclosed |
| US-20130310391-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-11-21 | — | — | US | disclosed |
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| WO-2012104007-A2 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-08-09 | — | — | WO | disclosed |
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| CN-101384592-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| EP-1979349-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310391-A1 | 7-AZAINDOLE DERIVATIVES | PDK1, PDK2, PDK3 | ADORA1 2955/4885ADORA2A 1822/4885AURKA 839/4885 |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | ADORA1 3948/4885ADORA2A 3844/4885AURKA 2172/4885 |
| US-20100256139-A1 | Anti-Viral Compounds | HAVCR2, MAVS, EIF2AK2 | ADORA1 3948/4885ADORA2A 3844/4885AURKA 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.